Peer-influenced content. Sources you trust. No registration required. This is HCN.

Monthly Prescribing Reference (MPR)July 2022 Notable Drug Approvals

FDA approved new indications for these drugs in July, include a Janus kinase inhibitor and a phosphodiesterase-4 inhibitor for use in dermatology, a carbonic anhydrase inhibitor for partial-onset seizures, and an expanded indication for the TKI crizotinib.